Vertex Pharmaceuticals Incorporated VRTX

526.19 3.81 0.73% as of 25 Sep
Market cap
$132.3B
P/E
30.4×
Indexes indicate stock being part of an index,
Growth Flags show if company had growth for consecutive years

Vertex Pharmaceuticals Incorporated (VRTX) P/E ratio

As of 25 September 2026, Vertex Pharmaceuticals Incorporated (VRTX) trades at a P/E ratio of 30.4×. Over the past ten years it has ranged from 0.0× (June 2025) to 194× (October 2017); the current reading is higher than 74% of that period. That is above the Biotechnology industry median of 7.9× and above the Healthcare sector median of 22.7×.

P/E ratio, daily

Annual

Period P/E ratio Change
FY2025 29.3× —
FY2024 0.0× —
FY2023 29.3× 32.82%
FY2022 22.0× (8.69%)
FY2021 24.1× 6.40%
FY2020 22.7× (52.66%)
FY2019 47.9× 138.24%
FY2018 20.1× (85.93%)
FY2017 143× —
FY2016 0.0× —

Quarterly

Period P/E ratio Change
Jun 2026 28.7× 9.19%
Mar 2026 26.3× (10.42%)
Dec 2025 29.3× 7.23%
Sep 2025 27.3× (13.20%)
42 more quarters

Against its own ten years

Low 0.0× High 194×
Ten-year median 24.9×
Current reading's percentile 74

P/E ratio against peers

Company P/E ratio
INSM Insmed, Inc. compare n/m
RVMD Revolution Medicines, Inc. compare n/m
MRNA Moderna, Inc. compare n/m
REGN Regeneron Pharmaceuticals, Inc. compare 18.8×
VRTX Vertex Pharmaceuticals Incorporated 30.4×
ARGX argenex SE compare 34.6×
RPRX Royalty Pharma PLC compare 40.1×
ALNY Alnylam Pharmaceuticals, Inc. compare 43.6×
ONC BeOne Medicines Ltd. - Sponsored ADR compare 61.2×
Biotechnology industry median 7.9×
Healthcare sector median 22.7×
Market median 17.9×

What P/E ratio is

Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.

Stock Price ÷ EPS (Basic) (TTM)

The full definition of P/E ratio →

More on VRTX